NCT05983107View on ClinicalTrials.gov

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2027

Conditions
HR+/HER2- Advanced Breast CancerTargeted Therapy
Interventions
DRUG

Everolimus

Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）

DRUG

Chidamide

Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）

DRUG

Endocrine therapy

Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.

DRUG

Ovarian function suppression(OFS)

Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER